Details for Patent: 8,367,685

Which drugs does patent 8,367,685 protect, and when does it expire?

Patent 8,367,685 protects OPSUMIT and is included in one NDA.

Protection for OPSUMIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,367,685

Title:	Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Abstract:	Stable pharmaceutical compositions include the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof:
Inventor(s):	Charles Tokunbo Adesuyi, Lovelace Holman, Olivier Lambert, Bruce Hamilton Lithgow
Assignee:	Actelion Pharmaceuticals Ltd
Application Number:	US12/388,142
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,367,685

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	OPSUMIT	macitentan	TABLET;ORAL	204410-001	Oct 18, 2013	AB	RX	Yes	Yes	8,367,685*PED				Y

Foreign Priority and PCT Information for Patent: 8,367,685

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP2005/009775	Sep 15, 2005

International Family Members for US Patent 8,367,685

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006290309
Brazil	PI0615898
Canada	2621273
China	101262847
Cyprus	1113395